Allogeneic hematopoietic cell transplantation in mantle cell lymphoma

Best Practice and Research: Clinical Haematology

Volumn 25, Issue 2, 2012, Pages 165-174

  Cassaday, Ryan D ^a   Gopal, Ajay K ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

allogeneic transplantation; mantle cell lymphoma

Indexed keywords

ALEMTUZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; HLA ANTIGEN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TENIPOSIDE; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; EVENT FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INDUCTION CHEMOTHERAPY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; EPIDEMIOLOGIC STUDIES; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MYELOABLATIVE AGONISTS; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84862236714     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.04.002     Document Type: Review

References (37)

1. M. Dreyling, and W. Hiddemann Current treatment standards and emerging strategies in mantle cell lymphoma Hematol Am Soc Hematol Educ Prog 2009 542 551
2. C.H. Geisler, A. Kolstad, and A. Laurell Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group Blood 112 2008 2687 2693
3. M. Dreyling, G. Lenz, and E. Hoster Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network Blood 105 2005 2677 2684 (Pubitemid 40450320)
4. L.E. Budde, K.A. Guthrie, and B.G. Till Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation J Clin Oncol 29 2011 3023 3029
5. C.H. Geisler, A. Kolstad, and A. Laurell The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT) Blood 115 2010 1530 1533
6. L.E. Budde, K.A. Guthrie, and B.G. Till Prognostic factors on outcome of mantle cell lymphoma patients relapsing after autologous hematopoietic stem cell transplantation Blood (ASH Annu Meet Abstracts) 114 2009 [Abstract 3327]
7. I.F. Khouri, M.S. Lee, and J. Romaguera Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy Ann Oncol 10 1999 1293 1299
8. A.D. Zelentz, J.A. Abramson, and R.A. Advani NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas (version 4.2011) 2011
9. I.F. Khouri, J. Romaguera, and H. Kantarjian Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma J Clin Oncol 16 1998 3803 3809 (Pubitemid 29001533)
10. A.M. Evens, J.N. Winter, and N. Hou A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma Br J Haematol 140 2008 385 393
11. C.S. Tam, R. Bassett, and C. Ledesma Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Blood 113 2009 4144 4152
12. Y.L. Kasamon, R.J. Jones, and L.F. Diehl Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma Biol Blood Marrow Transplant 11 2005 39 46 (Pubitemid 40057992)
13. N. Laudi, M. Arora, and L. Burns Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma Am J Hematol 81 2006 519 524
14. I.F. Khouri, M. Keating, and M. Korbling Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 16 1998 2817 2824 (Pubitemid 28363047)
15. P.A. McSweeney, D. Niederwieser, and J.A. Shizuru Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390 3400
16. M.L. Sorror, M.B. Maris, and R. Storb Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood 106 2005 2912 2919 (Pubitemid 41510773)
17. M.L. Sorror, B.M. Sandmaier, and B.E. Storer Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation J Clin Oncol 25 2007 4246 4254 (Pubitemid 47554249)
18. R. Rodriguez, A. Nademanee, and N. Ruel Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma Biol Blood Marrow Transplant 12 2006 1326 1334 (Pubitemid 44858267)
19. H. Bertz, G. Illerhaus, and H. Veelken Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens Ann Oncol 13 2002 135 139 (Pubitemid 34436737)
20. P. Armand, H.T. Kim, and V.T. Ho Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome Biol Blood Marrow Transplant 14 2008 418 425 (Pubitemid 351372748)
21. F. Baron, R. Storb, and B.E. Storer Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation J Clin Oncol 24 2006 4150 4157 (Pubitemid 46622292)
22. W.A. Bethge, T. Lange, and C. Meisner Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study Blood 116 2010 1795 1802
23. G. Cook, G.M. Smith, and K. Kirkland Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for blood and marrow transplantation Biol Blood Marrow Transplant 16 2010 1419 1427
24. P. Corradini, A. Dodero, and L. Farina Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome Leukemia 21 2007 2316 2323 (Pubitemid 350011704)
25. M. Hertzberg, A. Grigg, and D. Gottlieb Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders Bone Marrow Transplant 37 2006 923 928 (Pubitemid 43792552)
26. I.F. Khouri, M.S. Lee, and R.M. Saliba Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma J Clin Oncol 21 2003 4407 4412 (Pubitemid 46621818)
27. M.B. Maris, B.M. Sandmaier, and B.E. Storer Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma Blood 104 2004 3535 3542 (Pubitemid 39564424)
28. E. Morris, K. Thomson, and C. Craddock Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma Blood 104 2004 3865 3871 (Pubitemid 39620131)
29. S.P. Robinson, A.H. Goldstone, and S. Mackinnon Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation Blood 100 2002 4310 4316 (Pubitemid 35429668)
30. T. Shea, J. Johnson, and P. Westervelt Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901 Biol Blood Marrow Transplant 17 2011 1395 1403
31. A. Shimoni, S.T. Zwas, and Y. Oksman Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma Bone Marrow Transplant 41 2008 355 361 (Pubitemid 351330730)
32. A.K. Gopal, K.A. Guthrie, and J. Rajendran Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma Blood 118 2011 1132 1139
33. C. Kahl, B.E. Storer, and B.M. Sandmaier Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning Blood 110 2007 2744 2748 (Pubitemid 47523200)
34. M.M. Zhang, and A.K. Gopal Radioimmunotherapy-based conditioning regimens for stem cell transplantation Semin Hematol 45 2008 118 125 (Pubitemid 351444840)
35. N.H. Russell, J.L. Byrne, and R.D. Faulkner Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation Bone Marrow Transplant 36 2005 437 441 (Pubitemid 43115032)
36. K. Wudhikarn, C.G. Brunstein, and V. Bachanova Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome Biol Blood Marrow Transplant 17 2011 1497 1504
37. R. Ram, T.A. Gooley, and D.G. Maloney Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 17 2011 1537 1545